Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06567418
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients A Database-based Retrospective Analysis
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to investigate the effectiveness of in-hospital initiation of alirocumab combined with statin ezetimibe on major cardiovascular events MACE in Chinese ACS patients The main question it aims to answer is
whether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting
Data from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023 Patients diagnosed with STEMI NSTEMI or UA at admission were identified at the first step Then for intervention group patients who received alirocumab 75mg combined with statin ezetimibe during the ACS hospitalization including the discharge date will be included for control group patients who received statin ezetimibe during the ACS hospitalization will be included All enrolled patients were required to have at least one documented follow-up visit
whether early initiation PCKS9i in hospital could reduce recent cardiovascular event risk in Chinese ACS patients in real-world setting
Data from CCA Database-Chest Pain Center were screened for all ACS patients from 01-Jan 2021 to 31-Dec 2023 Patients diagnosed with STEMI NSTEMI or UA at admission were identified at the first step Then for intervention group patients who received alirocumab 75mg combined with statin ezetimibe during the ACS hospitalization including the discharge date will be included for control group patients who received statin ezetimibe during the ACS hospitalization will be included All enrolled patients were required to have at least one documented follow-up visit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None